메뉴 건너뛰기




Volumn 10, Issue , 2016, Pages 757-765

Potential for bispecific T-cell engagers: Role of blinatumomab in acute lymphoblastic leukemia

Author keywords

B cell lineage acute lymphoblastic leukemia; BiTE monoclonal antibodies; Blinatumomab; Minimal residual disease; Relapsed refractory

Indexed keywords

AMINOTRANSFERASE; BLINATUMOMAB; CD19 ANTIGEN; CD3 ANTIGEN; DEXAMETHASONE; GAMMA GLUTAMYLTRANSFERASE; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY;

EID: 84959468203     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S83848     Document Type: Review
Times cited : (24)

References (60)
  • 2
    • 84959490195 scopus 로고    scopus 로고
    • Accessed October 4, 2015
    • SEER Cancer Statistics Review [webpage on the Internet]. Previous Version: SEER Cancer Statistics Review, 1975–2010. 2015. Available from: http://seer.cancer.gov/archive/csr/1975_2010/. Accessed October 4, 2015.
    • (2015) Previous Version: SEER Cancer Statistics Review , pp. 1975-2010
  • 3
    • 84863772728 scopus 로고    scopus 로고
    • Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the children’s oncology group
    • Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol. 2012; 30(14):1663–1669.
    • (2012) J Clin Oncol , vol.30 , Issue.14 , pp. 1663-1669
    • Hunger, S.P.1    Lu, X.2    Devidas, M.3
  • 4
    • 84872825239 scopus 로고    scopus 로고
    • Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B Study 19802
    • Stock W, Johnson JL, Stone RM, et al. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer. 2013;119(1):90–98.
    • (2013) Cancer , vol.119 , Issue.1 , pp. 90-98
    • Stock, W.1    Johnson, J.L.2    Stone, R.M.3
  • 5
    • 77956240944 scopus 로고    scopus 로고
    • Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia
    • Thomas DA, O’Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28(24):3880–3889.
    • (2010) J Clin Oncol , vol.28 , Issue.24 , pp. 3880-3889
    • Thomas, D.A.1    O’Brien, S.2    Faderl, S.3
  • 6
    • 0027974256 scopus 로고
    • Neurofibromatosis and childhood leukaemia/lymphoma: A population-based UKCCSG study
    • Stiller CA, Chessells JM, Fitchett M. Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer. 1994;70(5):969–972.
    • (1994) Br J Cancer , vol.70 , Issue.5 , pp. 969-972
    • Stiller, C.A.1    Chessells, J.M.2    Fitchett, M.3
  • 7
    • 0018147038 scopus 로고
    • Shwachman’s syndrome and acute lymphoblastic leukaemia
    • Strevens MJ, Lilleyman JS, Williams RB. Shwachman’s syndrome and acute lymphoblastic leukaemia. Br Med J. 1978;2(6129):18.
    • (1978) Br Med J , vol.2 , Issue.6129
    • Strevens, M.J.1    Lilleyman, J.S.2    Williams, R.B.3
  • 8
    • 0026349029 scopus 로고
    • Bloom’s syndrome: The German experience
    • Passarge E. Bloom’s syndrome: the German experience. Ann Genet. 1991;34(3–4):179–197.
    • (1991) Ann Genet , vol.34 , Issue.3 , pp. 179-197
    • Passarge, E.1
  • 9
    • 0030051855 scopus 로고    scopus 로고
    • Leukemia and lymphoma in ataxia telangiectasia
    • Taylor AM, Metcalfe JA, Thick J, Mak YF. Leukemia and lymphoma in ataxia telangiectasia. Blood. 1996;87(2):423–438.
    • (1996) Blood , vol.87 , Issue.2 , pp. 423-438
    • Taylor, A.M.1    Metcalfe, J.A.2    Thick, J.3    Mak, Y.F.4
  • 10
    • 64049110710 scopus 로고    scopus 로고
    • Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia
    • De Jonge R, Tissing WJE, Hooijberg JH, et al. Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia. Blood. 2009;113(10):2284–2289.
    • (2009) Blood , vol.113 , Issue.10 , pp. 2284-2289
    • De Jonge, R.1    Tissing, W.2    Hooijberg, J.H.3
  • 11
    • 0027972308 scopus 로고
    • Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950–1987
    • Erratum in: Radiat Res. 1994;139(1):129
    • Preston DL, Kusumi S, Tomonaga M, et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950–1987. Radiat Res. 1994;137(2 suppl):S68–S97. Erratum in: Radiat Res. 1994;139(1):129.
    • (1994) Radiat Res , vol.137 , Issue.2 , pp. S68-S97
    • Preston, D.L.1    Kusumi, S.2    Tomonaga, M.3
  • 12
    • 33644545382 scopus 로고    scopus 로고
    • Infection, immune responses and the aetiology of childhood leukaemia
    • Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer. 2006;6(3):193–203.
    • (2006) Nat Rev Cancer , vol.6 , Issue.3 , pp. 193-203
    • Greaves, M.1
  • 13
    • 79955961315 scopus 로고    scopus 로고
    • The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications
    • Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–5032.
    • (2011) Blood , vol.117 , Issue.19 , pp. 5019-5032
    • Campo, E.1    Swerdlow, S.H.2    Harris, N.L.3    Pileri, S.4    Stein, H.5    Jaffe, E.S.6
  • 14
    • 0023874066 scopus 로고
    • Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults
    • Hoelzer D, Thiel E, Löffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood. 1988;71(1):123–131.
    • (1988) Blood , vol.71 , Issue.1 , pp. 123-131
    • Hoelzer, D.1    Thiel, E.2    Löffler, H.3
  • 15
    • 0033153105 scopus 로고    scopus 로고
    • Prospective karyotype analysis in adult acute lymphoblastic leukemia: The cancer and leukemia Group B experience
    • Wetzler M, Dodge RK, Mrózek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood. 1999;93(11):3983–3993.
    • (1999) Blood , vol.93 , Issue.11 , pp. 3983-3993
    • Wetzler, M.1    Dodge, R.K.2    Mrózek, K.3
  • 16
    • 84936101906 scopus 로고    scopus 로고
    • Personalized medicine in adult acute lymphoblastic leukemia
    • Hoelzer D. Personalized medicine in adult acute lymphoblastic leukemia. Haematologica. 2015;100(7):855–858.
    • (2015) Haematologica , vol.100 , Issue.7 , pp. 855-858
    • Hoelzer, D.1
  • 18
    • 66149141393 scopus 로고    scopus 로고
    • Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
    • Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113(18):4153–4162.
    • (2009) Blood , vol.113 , Issue.18 , pp. 4153-4162
    • Bassan, R.1    Spinelli, O.2    Oldani, E.3
  • 19
    • 0028938844 scopus 로고
    • A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and leukemia group B study 8811
    • Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995;85(8):2025–2037.
    • (1995) Blood , vol.85 , Issue.8 , pp. 2025-2037
    • Larson, R.A.1    Dodge, R.K.2    Burns, C.P.3
  • 20
    • 0025836549 scopus 로고
    • Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: A follow-up report
    • Linker CA, Levitt LJ, O’Donnell M, Forman SJ, Ries CA. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood. 1991;78(11):2814–2822.
    • (1991) Blood , vol.78 , Issue.11 , pp. 2814-2822
    • Linker, C.A.1    Levitt, L.J.2    O’Donnell, M.3    Forman, S.J.4    Ries, C.A.5
  • 21
    • 10044259800 scopus 로고    scopus 로고
    • Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia
    • Kantarjian H, Thomas D, O’Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101(12):2788–2801.
    • (2004) Cancer , vol.101 , Issue.12 , pp. 2788-2801
    • Kantarjian, H.1    Thomas, D.2    O’Brien, S.3
  • 22
    • 84860012521 scopus 로고    scopus 로고
    • Outcomes in older adults with acute lymphoblastic leukaemia (ALL): Results from the international MRC UKALL XII/ECOG2993 trial
    • Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol. 2012;157(4):463–471.
    • (2012) Br J Haematol , vol.157 , Issue.4 , pp. 463-471
    • Sive, J.I.1    Buck, G.2    Fielding, A.3
  • 23
    • 60949101218 scopus 로고    scopus 로고
    • Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: The GRAALL-2003 study
    • Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27(6):911–918.
    • (2009) J Clin Oncol , vol.27 , Issue.6 , pp. 911-918
    • Huguet, F.1    Leguay, T.2    Raffoux, E.3
  • 24
    • 0022263614 scopus 로고
    • Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries
    • Bleyer WA, Poplack DG. Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Semin Oncol. 1985;12(2): 131–148.
    • (1985) Semin Oncol , vol.12 , Issue.2 , pp. 131-148
    • Bleyer, W.A.1    Poplack, D.G.2
  • 25
    • 0029135378 scopus 로고
    • The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia
    • Cortes J, O’Brien SM, Pierce S, Keating MJ, Freireich EJ, Kantarjian HM. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood. 1995;86(6):2091–2097.
    • (1995) Blood , vol.86 , Issue.6 , pp. 2091-2097
    • Cortes, J.1    O’Brien, S.M.2    Pierce, S.3    Keating, M.J.4    Freireich, E.J.5    Kantarjian, H.M.6
  • 26
    • 84865709936 scopus 로고    scopus 로고
    • German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies
    • Gökbuget N, Kneba M, Raff T, et al; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120(9):1868–1876.
    • (2012) Blood , vol.120 , Issue.9 , pp. 1868-1876
    • Gökbuget, N.1    Kneba, M.2    Raff, T.3
  • 27
    • 84927729448 scopus 로고    scopus 로고
    • Finally moving forward in adult ALL
    • Litzow MR. Finally moving forward in adult ALL. Blood. 2015;125(16):2453–2454.
    • (2015) Blood , vol.125 , Issue.16 , pp. 2453-2454
    • Litzow, M.R.1
  • 28
    • 84872295739 scopus 로고    scopus 로고
    • Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: An individual patient data meta-analysis
    • G
    • Gupta V, Richards S, Rowe J. Acute Leukemia Stem Cell Transplantation Trialists’ Collaborative Group. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. Blood. 2013;121(2):339–350.
    • (2013) Blood , vol.121 , Issue.2 , pp. 339-350
    • Upta, V.1    Richards, S.2    Rowe, J.3
  • 29
    • 33846869976 scopus 로고    scopus 로고
    • Medical Research Council of the United Kingdom Adult ALL Working Party; Eastern Cooperative Oncology Group. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
    • Fielding AK, Richards SM, Chopra R, et al; Medical Research Council of the United Kingdom Adult ALL Working Party; Eastern Cooperative Oncology Group. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109(3):944–950.
    • (2007) Blood , vol.109 , Issue.3 , pp. 944-950
    • Fielding, A.K.1    Richards, S.M.2    Chopra, R.3
  • 30
    • 84866094086 scopus 로고    scopus 로고
    • German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation
    • Gökbuget N, Stanze D, Beck J, et al; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120:2032–2041.
    • (2012) Blood , vol.120 , pp. 2032-2041
    • Gökbuget, N.1    Stanze, D.2    Beck, J.3
  • 31
    • 34548136113 scopus 로고    scopus 로고
    • Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial
    • Tavernier E, Boiron JM, Huguet F, et al; GET-LALA Group; Swiss Group for Clinical Cancer Research SAKK; Australasian Leukaemia and Lymphoma Group. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007;21:1907–1914.
    • (2007) Leukemia , vol.21 , pp. 1907-1914
    • Tavernier, E.1    Boiron, J.M.2    Huguet, F.3
  • 32
    • 0141482004 scopus 로고    scopus 로고
    • Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia
    • Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003;102(7):2379–2386.
    • (2003) Blood , vol.102 , Issue.7 , pp. 2379-2386
    • Kantarjian, H.1    Gandhi, V.2    Cortes, J.3
  • 33
    • 84934438248 scopus 로고    scopus 로고
    • Phase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemi
    • Abbi KKS, Rybka W, Ehmann WC, Claxton DF. Phase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemia. Clin Lymphoma Myeloma Leuk. 2015;15(1): 41–46.
    • (2015) Clin Lymphoma Myeloma Leu , vol.1 , Issue.51 , pp. 41-44
    • Abbi, K.1    Rybka, W.2    Ehmann, W.C.C.D.3
  • 34
    • 84923019411 scopus 로고    scopus 로고
    • Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia
    • Le Jeune C, Thomas X. Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia. Eur J Haematol. 2015;94:99–108.
    • (2015) Eur J Haematol , vol.94 , pp. 99-108
    • Le Jeune, C.1    Thomas, X.2
  • 35
    • 84876325876 scopus 로고    scopus 로고
    • Chimeric antigen receptor-modified T cells for acute lymphoid leukemia
    • Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–1518.
    • (2013) N Engl J Med , vol.368 , Issue.16 , pp. 1509-1518
    • Grupp, S.A.1    Kalos, M.2    Barrett, D.3
  • 36
    • 84869145679 scopus 로고    scopus 로고
    • Monoclonal antibody-based therapies: A new dawn in the treatment of acute lymphoblastic leukemia
    • Kantarjian H, Thomas D, Wayne AS, O’Brien S. Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. J Clin Oncol. 2012;30(31):3876–3883.
    • (2012) J Clin Oncol , vol.30 , Issue.31 , pp. 3876-3883
    • Kantarjian, H.1    Thomas, D.2    Wayne, A.S.3    O’Brien, S.4
  • 37
    • 84922961118 scopus 로고    scopus 로고
    • Current status of antibody therapy in ALL
    • Ai J, Advani A. Current status of antibody therapy in ALL. Br J Haematol. 2015;168(4):471–480.
    • (2015) Br J Haematol , vol.168 , Issue.4 , pp. 471-480
    • Ai, J.1    Advani, A.2
  • 38
    • 79957450612 scopus 로고    scopus 로고
    • Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: Analysis of 552 cases
    • Raponi S, De Propris MS, Intoppa S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011;52(6):1098–1107.
    • (2011) Leuk Lymphoma , vol.52 , Issue.6 , pp. 1098-1107
    • Raponi, S.1    De Propris, M.S.2    Intoppa, S.3
  • 39
    • 0032147183 scopus 로고    scopus 로고
    • CD19 regulates B lymphocyte responses to transmembrane signals
    • Fujimoto M, Poe JC, Inaoki M, Tedder TF. CD19 regulates B lymphocyte responses to transmembrane signals. Semin Immunol. 1998;10(4): 267–277.
    • (1998) Semin Immunol , vol.10 , Issue.4 , pp. 267-277
    • Fujimoto, M.1    Poe, J.C.2    Inaoki, M.3    Tedder, T.F.4
  • 40
    • 79953112441 scopus 로고    scopus 로고
    • Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation
    • Baracho GV, Miletic AV, Omori SA, Cato MH, Rickert RC. Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation. Curr Opin Immunol. 2011;23(2):178–183.
    • (2011) Curr Opin Immunol , vol.23 , Issue.2 , pp. 178-183
    • Baracho, G.V.1    Miletic, A.V.2    Omori, S.A.3    Cato, M.H.4    Rickert, R.C.5
  • 41
    • 0037143806 scopus 로고    scopus 로고
    • Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody
    • Dreier T, Lorenczewski G, Brandl C, et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer. 2002; 100(6):690–697.
    • (2002) Int J Cancer , vol.100 , Issue.6 , pp. 690-697
    • Dreier, T.1    Lorenczewski, G.2    Brandl, C.3
  • 43
    • 79955662260 scopus 로고    scopus 로고
    • Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
    • Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res. 2011; 317(9):1255–1260.
    • (2011) Exp Cell Res , vol.317 , Issue.9 , pp. 1255-1260
    • Nagorsen, D.1    Baeuerle, P.A.2
  • 44
    • 28944434529 scopus 로고    scopus 로고
    • Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells
    • Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol. 2006; 43(6):763–771.
    • (2006) Mol Immunol , vol.43 , Issue.6 , pp. 763-771
    • Offner, S.1    Hofmeister, R.2    Romaniuk, A.3    Kufer, P.4    Baeuerle, P.A.5
  • 45
    • 84959571834 scopus 로고    scopus 로고
    • Accessed October 11, 2015
    • ® (blinatumomab). Available from: http://pi.amgen.com/united_states/blincyto/blincyto_pi_hcp_english.pdf. Accessed October 11, 2015.
  • 46
    • 84922430955 scopus 로고    scopus 로고
    • Pharmacokinetics (PK) of blinatumomab and its clinical implications
    • abstract 3048
    • Wu B, Hijazi Y, Wolf A, Brandl C, Sun YN, Zhu M. Pharmacokinetics (PK) of blinatumomab and its clinical implications. J Clin Oncol. 2013; 31(15):abstract 3048.
    • (2013) J Clin Oncol , vol.31 , Issue.15
    • Wu, B.1    Hijazi, Y.2    Wolf, A.3    Brandl, C.4    Sun, Y.N.5    Zhu, M.6
  • 47
    • 84947484898 scopus 로고    scopus 로고
    • Blinatumomab for the treatment of acute lymphoblastic leukemia
    • Kaplan JB, Grischenko M, Giles FJ. Blinatumomab for the treatment of acute lymphoblastic leukemia. Invest New Drugs. 2015;33(6):1271–1279.
    • (2015) Invest New Drugs , vol.33 , Issue.6 , pp. 1271-1279
    • Kaplan, J.B.1    Grischenko, M.2    Giles, F.J.3
  • 48
    • 49649120397 scopus 로고    scopus 로고
    • Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
    • Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321(5891):974–977.
    • (2008) Science , vol.321 , Issue.5891 , pp. 974-977
    • Bargou, R.1    Leo, E.2    Zugmaier, G.3
  • 49
    • 84863522243 scopus 로고    scopus 로고
    • Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
    • Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119(26):6226–6233.
    • (2012) Blood , vol.119 , Issue.26 , pp. 6226-6233
    • Klinger, M.1    Brandl, C.2    Zugmaier, G.3
  • 50
    • 79959312575 scopus 로고    scopus 로고
    • Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival
    • Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493–2498.
    • (2011) J Clin Oncol , vol.29 , Issue.18 , pp. 2493-2498
    • Topp, M.S.1    Kufer, P.2    Gökbuget, N.3
  • 51
    • 84871491706 scopus 로고    scopus 로고
    • Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
    • Topp MS, Gökbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120(26):5185–5187.
    • (2012) Blood , vol.120 , Issue.26 , pp. 5185-5187
    • Topp, M.S.1    Gökbuget, N.2    Zugmaier, G.3
  • 53
    • 84916639631 scopus 로고    scopus 로고
    • Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia
    • Topp MS, Gökbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32(36):4134–4140.
    • (2014) J Clin Oncol , vol.32 , Issue.36 , pp. 4134-4140
    • Topp, M.S.1    Gökbuget, N.2    Zugmaier, G.3
  • 54
    • 84926099033 scopus 로고    scopus 로고
    • Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study
    • Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57–66.
    • (2015) Lancet Oncol , vol.16 , Issue.1 , pp. 57-66
    • Topp, M.S.1    Gökbuget, N.2    Stein, A.S.3
  • 55
    • 84903632926 scopus 로고    scopus 로고
    • Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
    • Schlegel P, Lang P, Zugmaier G, et al. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica. 2014;99(7):1212–1219.
    • (2014) Haematologica , vol.99 , Issue.7 , pp. 1212-1219
    • Schlegel, P.1    Lang, P.2    Zugmaier, G.3
  • 56
    • 84934324966 scopus 로고    scopus 로고
    • Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia
    • Ribera J-M, Ferrer A, Ribera J, Genescà E. Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia. Onco Targets Ther. 2015;8:1567–1574.
    • (2015) Onco Targets Ther , vol.8 , pp. 1567-1574
    • Ribera, J.-M.1    Ferrer, A.2    Ribera, J.3    Genescà, E.4
  • 57
    • 84895066532 scopus 로고    scopus 로고
    • Toxicity management for patients receiving novel T-cell engaging therapies
    • Barrett DM, Teachey DT, Grupp SA. Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr. 2014; 26(1):43–49.
    • (2014) Curr Opin Pediatr , vol.26 , Issue.1 , pp. 43-49
    • Barrett, D.M.1    Teachey, D.T.2    Grupp, S.A.3
  • 58
    • 84882782587 scopus 로고    scopus 로고
    • Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
    • Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121(26):5154–5157.
    • (2013) Blood , vol.121 , Issue.26 , pp. 5154-5157
    • Teachey, D.T.1    Rheingold, S.R.2    Maude, S.L.3
  • 59
    • 84959542798 scopus 로고    scopus 로고
    • Complete molecular and hematologic response in adult patients with relapsed/refractory (R/R) Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (ALL) following treatment with blinatumomab: Results from a phase 2 single-arm, multicenter study (ALCANTARA)
    • abstract 679
    • Martinelli G, Dombret H, Chevallier P, et al. Complete molecular and hematologic response in adult patients with relapsed/refractory (R/R) Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (ALL) following treatment with blinatumomab: results from a phase 2 single-arm, multicenter study (ALCANTARA). Blood. 2015;126(issue 23):abstract 679.
    • (2015) Blood , vol.126 , Issue.23
    • Martinelli, G.1    Dombret, H.2    Chevallier, P.3
  • 60
    • 84908073316 scopus 로고    scopus 로고
    • Chimeric antigen receptor T cells for sustained remissions in leukemia
    • Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517.
    • (2014) N Engl J Med , vol.371 , Issue.16 , pp. 1507-1517
    • Maude, S.L.1    Frey, N.2    Shaw, P.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.